Registro de medicamentos com indicação agnóstica já é realidade no Brasil, o que significa para a judicialização?

Sidaway P. Larotrectinib effective against TRK-fusion-positive cancers. Nat Rev Clin Oncol [Internet]. 2018 May 13;15(5):264–264. Disponível em: http://www.nature.com/articles/nrclinonc.2018.40 Offin M, Liu D, Drilon A. Tumor-Agnostic Drug Development. Am Soc Clin Oncol Educ B [Internet]. 2018 May 23;(38):184–7. Disponível em: https://doi.org/10.1200/EDBK_200831 U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. [Internet]. 2018 [Acesso em 02 agosto 2019]. Disponível em: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm Lacombe D, Burock S, Bogaerts J, Schoeffski P, Golfinopoulos V, Stupp R. The dream and reality of histology agnostic cancer clinical trials. Mol Oncol [Internet]. 2014 Sep 12;8(6):1057–63. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/25349876 Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, et al. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. J Clin Oncol [Internet]. 2017;35(3):271–3. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/27893325 Chen C, Li X (Nicole), Yuan S, Antonijevic Z, Kalamegham R, Beckman RA. Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study. Stat Biopharm Res [Internet]. 2016 Jul 2;8(3):248–57. Disponível em: https://www.tandfonline.com/doi/full/10.1080/19466315.2016.1193044 Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, et al. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv [Internet]. 2019 Jul 23;3(14):2237–43. Disponível em: http://www.bloodadvances.org/lookup/doi/10.1182/bloodadvances.2019031229 Cunanan KM, Iasonos A, Shen R, Hyman DM, Riely GJ, Gönen M, et al. Specifying the True- and False-Positive Rates in Basket Trials. JCO Precis Oncol [Internet]. 2017 Nov 1;(1):1–5. Disponível em: https://doi.org/10.1200/PO.17.00181 Chen AP, Eljanne M, Harris L, Malik S, Seibel NL. National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond. Cancer J [Internet]. 25(4):272–81. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/31335391 Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med [Internet]. 2018;378(8):731–9. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29466156 U.S. Food and Drug Administration. Fast Track [Internet]. [Acesso em 29 Jul 2019]. Disponível em: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS, et al. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. J Clin Oncol [Internet]. 2018;36(18):1805–12. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29688832 Naci H, Smalley KR, Kesselheim AS. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. JAMA [Internet]. 2017 Aug 15;318(7):626–36. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/28810023 Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, et al. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ [Internet]. 2018;361:k2031. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29794072 Chen EY, Raghunathan V, Prasad V. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Intern Med [Internet]. 2019 May 28; Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/31135822 Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Intern Med [Internet]. 2019 Jul 1;179(7):906. Disponível em: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2019.0462 Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials [Internet]. 2016;13(3):358–66. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/26908536 Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med [Internet]. 2017;377(1):62–70. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/28679092 Berry DA. The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol [Internet]. 2015 May;9(5):951–9. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/25888066 Catenacci DVT. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol [Internet]. 2015 May;9(5):967–96. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/25557400 Yan L, Zhang W. Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun (London, England) [Internet]. 2018;38(1):6. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29764494 Le Tourneau C, Kamal M, Bièche I. Precision medicine in oncology: what is it exactly and where are we? Per Med [Internet]. 2018 Sep;15(5):351–3. Disponível em: https://www.futuremedicine.com/doi/10.2217/pme-2018-0036 Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discov [Internet]. 2018 Feb;8(2):174–83. Disponível em: http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-17-0321 Buljan M, Blattmann P, Aebersold R, Boutros M. Systematic characterization of pan‐cancer mutation clusters. Mol Syst Biol [Internet]. 2018 Mar 23;14(3):e7974. Disponível em: http://msb.embopress.org/lookup/doi/10.15252/msb.20177974 Bartels S, Schipper E, Hasemeier B, Kreipe H, Lehmann U. Hotspot mutations in cancer genes may be missed in routine diagnostics due to neighbouring sequence variants. Exp Mol Pathol [Internet]. 2018 Aug;105(1):37–40. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0014480018301734 Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol [Internet]. 2016 Feb;34(2):155–63. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/26619011 Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol [Internet]. 2018 Nov;2(1):1–20. Disponível em: http://ascopubs.org/doi/10.1200/PO.18.00183 Knight TG, Deal AM, Dusetzina SB, Muss HB, Choi SK, Bensen JT, et al. Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. J Oncol Pract [Internet]. 2018 Oct 24;JOP1800120. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/30355027 Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med [Internet]. 2018 May;6(9):166–166. Disponível em: http://atm.amegroups.com/article/view/19114/19491 World Health Organization. Pricing of cancer medicines and its impacts [Internet]. 2018. [Acesso em 29 Jul 2019]. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.pdf Bayer. TRAK AssistTM [Internet]. [Acesso em 29 Jul 2019]. Disponível em: https://www.hcp.vitrakvi-us.com/access/